Rituximab shows promise in preventing vasculitis relapses
NCT ID NCT00748644
First seen Nov 20, 2025 · Last updated Jun 22, 2026 · Updated 24 times
Summary
This study tested whether rituximab, a targeted antibody therapy, is better than azathioprine, a standard immune-suppressing drug, at preventing relapses in people with ANCA-associated vasculitis. 117 patients who had achieved remission were randomly assigned to receive either rituximab infusions or azathioprine pills over 18 months. The main goal was to see how many had a major relapse during treatment and follow-up.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MICROSCOPIC POLYANGIITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hopital Cochin
Paris, 75014, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rituximab
What this could lead to
If successful, rituximab could become a standard maintenance therapy to prevent relapses in vasculitis patients, reducing the need for long-term steroids.
What could go wrong
This is a Phase 3 trial, but results may not apply to all patients. Rituximab can cause infusion reactions and increase infection risk. The study is completed, so findings are available but not yet widely implemented.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.